Skip to content

Serotonin: all studies

Page 292 of 401: studies 2,911 to 2,920 of 4,004, newest first. Back to the serotonin overview

Research

O Uso da Ayahuasca como terapia alternativa na depressão: efeitos farmacológicos e adversos

Brazilian Journal of Natural Sciences October 12, 2021 Beatriz Souza Silva, Giovanna Pereira Lima, Isabela Rodrigues Alencar Dos Santos et al. 2 citations

Doença comum atualmente, a depressão, quando diagnosticada, é tratada com fármacos antidepressivos, sendo os inibidores seletivos da receptação de serotonina (ISRSs) considerados os de primeira escolha. Tanto esta quanto as demais classes de antidepressivos costumam apresentar efeitos adversos, que muitas vezes levam ao abandono do tratamento pelo paciente. Um outro desafio no tratamento da...

DOI: 10.31415/bjns.v4i2.143 (opens in new tab) Pharmacology Traditional medicine

Many Drugs of Abuse May Be Acutely Transformed to Dopamine, Norepinephrine and Epinephrine In Vivo

International Journal of Molecular Sciences October 2, 2021 Paul J. Fitzgerald 30 citations

It is well established that a wide range of drugs of abuse acutely boost the signaling of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, where norepinephrine and epinephrine are major output molecules. This stimulatory effect is accompanied by such symptoms as elevated heart rate and blood pressure, more rapid breathing, increased body temperature and...

DOI: 10.3390/ijms221910706 (opens in new tab) Dopamine Norepinephrine In vivo Pharmacology +2

Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice

Cell Reports October 1, 2021 Mario de la Fuente Revenga, Bohan Zhu, Christopher A. Guevara et al.

SUMMARY Clinical evidence suggests that rapid and sustained antidepressant action can be attained with a single exposure to psychedelics. However, the biological substrates and key mediators of psychedelics’ enduring action remain unknown. Here, we show that a single administration of the psychedelic DOI produces fast-acting effects on frontal cortex dendritic spine structure and acceleration...

Novel antidepressant drugs: Beyond monoamine targets

CNS Spectrums September 30, 2021 Xénia Gonda, Péter Döme, Joanna C. Neill et al. 77 citations

Abstract Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need. Although there are several classes of dissimilar antidepressant drugs approved for MDD, the current drugs have either limited efficacy or are associated with undesirable side effects and withdrawal symptoms. The efficacy and side effects of antidepressant drugs are...

DOI: 10.1017/s1092852921000791 (opens in new tab) Major depressive disorder Antidepressant Monoamine neurotransmitter Tolerability +2

Psychedelics, Sociality, and Human Evolution

Frontiers in Psychology September 29, 2021 José Manuel Rodríguez-arce, Michael James Winkelman 80 citations

Our hominin ancestors inevitably encountered and likely ingested psychedelic mushrooms throughout their evolutionary history. This assertion is supported by current understanding of: early hominins’ paleodiet and paleoecology; primate phylogeny of mycophagical and self-medicative behaviors; and the biogeography of psilocybin-containing fungi. These lines of evidence indicate mushrooms...

DOI: 10.3389/fpsyg.2021.729425 (opens in new tab) Sociality Context archaeology Cognition Cognitive psychology +1

Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics

TIPS - Trends in Pharmacological Sciences September 24, 2021 Lily R. Aleksandrova, Anthony G. Phillips 255 citations

The emerging therapeutic efficacy of ketamine and classical psychedelics for depression has inspired tremendous interest in the underlying neurobiological mechanisms. We review preclinical and clinical evidence supporting neuroplasticity as a convergent downstream mechanism of action for these novel fast-acting antidepressants. Through their primary glutamate or serotonin receptor targets,...

The therapeutical role of psychedelic drugs in treatment of mental disorders

Bulletin of Integrative Psychiatry September 15, 2021 Dan Cătălin Oprea, Loretta Epure, Vasile Chiriță et al.

Psychedelic drugs (also called hallucinogens, psychotogenics, psycholytics, entheogens) are substances that act mainly on the 5-HT2 serotonergic receptor.There are two main groups of psychedelics: indoleamines (lysergic acid diethylamide-LSD, N, N-dimethyltryptamine-DMT, and psilocybin) and phenethylamines (mescaline, dimethoxymethamphetamine-DOM, methylenedioxyamphetamine-MDA, and...

LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1

Scientific Reports September 5, 2021 Ramona M. Rodriguiz, Vineet Nadkarni, Christopher R. Means et al. 92 citations

Abstract Recent evidence suggests that psychedelic drugs can exert beneficial effects on anxiety, depression, and ethanol and nicotine abuse in humans. However, their hallucinogenic side-effects often preclude their clinical use. Lysergic acid diethylamide (LSD) is a prototypical hallucinogen and its psychedelic actions are exerted through the 5-HT2A serotonin receptor (5-HT2AR). 5-HT2AR...

Anxiety, depression-like behaviors and biochemistry disorders induced by cannabis extract in female mice

Saudi Journal of Biological Sciences September 1, 2021 Atheer M. Mohammed, Ibrahim A. Khardali, Magbool E. Oraiby et al. 7 citations

Cannabis is an annual herbaceous plant sometimes grown for decoration and used as bird food that looks like flax. The study wanted to determine if a Cannabis extract may have an effect on how anxious and depressed the female mice behaved. forty healthy female mice were divided into four groups. Tap water was administered to the first group (control). Ethanol was administered to second group...

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.

European Neuropsychopharmacology September 1, 2021 Martin K Madsen, Dea S Stenbæk, Albin Arvidsson et al. 132 citations

The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active metabolite). The serotonin 2A receptor critically mediates these effects by altering distributed neural processes that manifest as increased entropy, reduced functional connectivity (FC) within discrete brain networks (i.e., reduced integrity) and increased...